Clinical Trials Browser

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00809237 2013-12-10

Hydroxychloroquine and Gefitinib to Treat Lung Cancer

Phase 1/2 Unknown

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00268255 2013-04-16

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00098462 2012-10-04

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

GOAL

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

MK-3475-021

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Hydroxychloroquine and Gefitinib to Treat Lung Cancer

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer